In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization